DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 03 · Volume 35 · May 2002 DOI: 10.1055/s-002-1964

Review

83
Brieden, T.; Ujeyl, M.; Naber, D.: Psychopharmacological Treatment of Aggression in Schizophrenic Patients

Original Paper

90
Henning, U.; Löffler, S.; Krieger, K.; Klimke, A.: Uptake of Clozapine into HL-60 Promyelocytic Leukaemia Cells
96
Eschweiler, G. W.; Bartels, M.; Längle, G.; Wild, B.; Gaertner, I.; Nickola, M.: Heart-Rate Variability (HRV) in the ECG Trace of Routine EEGs: Fast Monitoring for the Anticholinergic Effects of Clozapine and Olanzapine?
101
Buchberger, R.; Wagner, W.: Fluvoxamine: Safety Profile in Extensive Post-Marketing Surveillance

Case Report

109
Wetter, T. C.; Brunner, J.; Bronisch, T.: Restless Legs Syndrome Probably Induced by Risperidone Treatment
112
Azaz-Livshits, T.; Hershko, A.; Ben-Chetrit, E.: Paroxetine Associated Hepatotoxicity: A Report of 3 Cases and a Review of the Literature
116
Köhnke, M. D.; Griese, E.-U.; Stösser, D.; Gaertner, I.; Barth, G.: Cytochrome P450 2D6 Deficiency and its Clinical Relevance in a Patient Treated with Risperidone
119
Bottlender, R.; Jäger, M.; Hofschuster, E.; Dobmeier, P.; Möller, H.-J.: Neuroleptic Malignant Syndrome due to Atypical Neuroleptics: Three Episodes in One Patient
122
Mendhekar, D. N.; War, L.; Sharma, J. B.; Jiloha, R. C.: Olanzapine and Pregnancy
124
Virkkunen, M.; Wahlbeck, K.; Rissanen, A.; Naukkarinen, H.; Franssila-Kallunki, A.: Decrease of Energy Expenditure Causes Weight Increase in Olanzapine Treatment - A Case Study